Elucidation of the Effects of Antidiabetic Drugs on the Progression of Diabetic Nephropathy via the Bacteria-Derived Peptide Corisin

Elucidation of the Effects of Antidiabetic Drugs on the Progression of Diabetic Nephropathy via the Bacteria-Derived Peptide Corisin - Elucidation of the Effects of Antidiabetic Drugs on the Progression of Diabetic Nephropathy via the Bacteria-Derived Peptide Corisin

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061824

Enrollment

200

Registered

2026-06-08

Start date

2026-05-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients scheduled to receive treatment with metformin, SGLT2 inhibitors, GLP-1 receptor agonists, or GLP-1/GIP receptor agonists at Mie University Hospital. Patients aged 20 years or older. Patients (or their legally authorized representatives) who provide written informed consent.

Exclusion criteria

Exclusion criteria: Patients whom the principal investigator or a sub-investigator judges to be unsuitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
In this study, we will investigate whether administration of the target drugs (metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and GLP-1/GIP receptor agonists) alters the systemic levels of the microbiota-derived peptide corisin and examine its association with parameters related to the progression of vascular complications, including diabetic nephropathy. These parameters will include clinical laboratory data obtained during routine medical care, patient background information extracted from electronic medical records, and results of corisin-related laboratory analyses performed in our research laboratory.	—

Measure

Time frame

In this study, we will investigate whether administration of the target drugs (metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and GLP-1/GIP receptor agonists) alters the systemic levels of the microbiota-derived peptide corisin and examine its association with parameters related to the progression of vascular complications, including diabetic nephropathy. These parameters will include clinical laboratory data obtained during routine medical care, patient background information extracted from electronic medical records, and results of corisin-related laboratory analyses performed in our research laboratory.

—

Secondary

Measure	Time frame
Effects on Glycemic Control Effects on Lipid Profiles Effects on Body Weight and Body Composition Effects on Vascular Complications Effects on Liver Function	—

Countries

Japan

Contacts

Public ContactChisa Inoue

Mie University Department of Diabetes, Metabolism, and Endocrinology

chisa0417@med.mie-u.ac.jp059-232-1111

Outcome results